Option chain shows key data for FibroBiologics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for FibroBiologics.

FibroBiologics (NASDAQ:FBLG) Stock, Option Chain

FibroBiologics

FibroBiologics, Inc. - Common Stock

FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.

Stock market analysts

News

Initiation

Markets

Analyst Ratings

Trading Ideas

CARM

FBLG

IVVD

This NANO Nuclear Energy Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Wednesday

Image22

Pre-Market Outlook

Movers

BBCP

BMEA

DOCU

FTEL

REPL

Vail Resorts Posts Downbeat Q3 Results, Joins Concrete Pumping, DocuSign And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

xr:d:DAFtH5xd8iU:2,j:4016486423666345323,t:23083115

Intraday Update

AMBC

ASNS

BGXX

BNED

CLEU

CMPS

CVAC

DLTR

DOYU

FRES

GDHG

GWRE

HLTH

JDZG

JEWL

MITQ

MLGO

MMYT

MNMD

MPLN

MYND

NDRA

NVAX

NVVE

OLLI

SFIX

SGRP

SILO

SOBR

SYTA

THMO

UMAC

UNFI

VLCN

VRNT

VSTE

WKME

XTIA

Why Lands&#39; End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

FibroBiologics Inc

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) with a Buy and raises the price target from $40 to $42.

Price Target

AVXL

HC Wainwright & Co. Maintains Buy on Anavex Life Sciences, Raises Price Target to $42

Chinese EV startup Nio Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) launched its new lower-priced EV brand Onvo in May this year. The brand started selling its first vehicle- the Onvo L60- in late September and since then, Nio sales have been on the rise.
What Happened: The Onvo L60 is a mid-size electric SUV that starts at 206,900 yuan ($28,347) with the battery pack included, much lower than Tesla&#8217;s affordable models Model 3 or Model Y in China.
In September, Nio delivered 832 Onvo L60s despite having only a few selling days. In October, the first full month of sales, Onvo deliveries rose to 4,319. In November, L60 deliveries rose to 5,082, implying demand for the vehicle. 
In August, the month before Onvo deliveries commenced, Nio delivered 20,176 vehicles, marking a growth of just 4.4% year-on-year.
In September, the first month of Onvo L60 deliveries, Nio&#8217;s total deliveries jumped 35.4% as compared to the corresponding period last year. In October and November, deliveries <a href="https://www.benzinga.com/24/12/42260165/li-auto-xpeng-nio-heres-how-november-deliveries-of-chinese-ev-startups-stack-up">marked an increase of 30.5% and 29%</a>, respectively.
Why It Matters: Nio identifies itself as a premium EV brand. Its ET9, for instance, starts at 788,000 yuan, including the battery. 
The low-cost EV from the company&#8217;s Onvo brand has helped it move to the low-cost EV segment which has significant demand.
Earlier this month, Nio also <a href="https://www.benzinga.com/24/12/42550944/whats-going-on-with-nio-stock-today">launched a new brand called Firefly</a>, touted as a rival to Mercedes&#8217; Smart and BMW&#8217;s Mini. The brand&#8217;s first vehicle shares its name and pre-sales started at a price of 148,800 yuan. It is expected to be launched in April 2025.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/12/42668333/tesla-model-x-lucid-gravity-or-rivian-r1s-which-three-row-electric-suv-is-a-better-buy" target="_blank" rel="noreferrer noopener">Tesla Model X, Lucid Gravity Or Rivian R1S: Which Three-Row Electric SUV Is A Better Buy?</a></li>
</ul>
Photo courtesy: Nio

Tech

Nio's Onvo Brand Helps Spur Delivery Growth With Cheaper Offering

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains PolyPid (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPD#NASDAQ">PYPD</a>) with a Buy and lowers the price target from $14 to $11.

PYPD

HC Wainwright & Co. Maintains Buy on PolyPid, Lowers Price Target to $11

Raymond James analyst C. Gregory Peters maintains Kemper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMPR#NYSE">KMPR</a>) with a Strong Buy and raises the price target from $75 to $82.

KMPR

Raymond James Maintains Strong Buy on Kemper, Raises Price Target to $82

Earnings

NVNI

Nvni Group Reported FY23 Revenue Growth Of 36% YoY

SATS

Microelectronics Technology Enters Strategic Partnership With EchoStar To Advance Development Of Energy-Efficient Open RAN Macro Radios With NTIA Grant

HC Wainwright &amp; Co. analyst Raghuram Selvaraju upgrades RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) from Neutral to Buy and maintains the price target from $10 to $10.

Upgrades

RAPT

HC Wainwright & Co. Upgrades RAPT Therapeutics to Buy, Maintains Price Target to $10

Demand for <a target="_blank" href="https://www.benzinga.com/topic/ai" rel="noreferrer noopener">artificial intelligence-enabled</a> smartphones could serve as a buffer for parts of the semiconductor industry against a potential slowdown in data center investments, Financial Times <a target="_blank" href="https://www.ft.com/content/54c3d188-9c5d-4664-94c4-366207ef9aad" rel="noreferrer noopener">cites</a> Doug Lefever, CEO of Advantest, a Japanese supplier of chip testing equipment for Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
Lefever expressed concern over possible dips in spending by <a target="_blank" href="https://www.benzinga.com/news/24/09/41066968/microsoft-google-meta-pave-path-to-ai-expansion-nvidia-and-broadcom-set-to-reap-benefits" rel="noreferrer noopener">major U.S. tech companies</a>, such as Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google, and Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), which have been driving the construction of advanced data centers.
Lefever told the FT that while fluctuations in data center spending may not last long, any decline could significantly disrupt the semiconductor supply chain due to its reliance on hyperscalers.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42675098/netflix-takes-vmware-to-court-over-patent-infringement-claims" rel="noreferrer noopener">Broadcom and Netflix Clash Over Patent Disputes Ahead of 2025 Trial</a>
He added that the industry&#8217;s cyclical nature could lead to what he described as &#8220;vicious&#8221; downturns. However, he remained optimistic about the potential growth of AI smartphones, suggesting that a breakthrough application could rapidly drive consumer demand and spark a wave of handset replacements.
Advantest, headquartered in Tokyo, holds over 50% of the semiconductor testing market and has benefited from the rising complexity and cost of chips.
Lefever highlighted the growing complexity of chip testing, with Nvidia&#8217;s latest Blackwell products requiring three to four times longer to test than previous generations, as a key driver of sustained demand for Advantest&#8217;s solutions.
The company&#8217;s success extends to high-end testing equipment, which costs $1 million per unit and boasts a market share exceeding 60% in specific categories. Despite geopolitical challenges, such as U.S. restrictions on China, Lefever told the FT that increased demand elsewhere quickly offset lost sales in China. He emphasized that Advantest remains well-positioned globally, with operations in 18 countries and a diversified customer base.
Apple began introducing its <a target="_blank" href="https://www.benzinga.com/news/24/10/41526650/apples-ai-powered-future-iphone-growth-surge-by-2026-with-new-iphone-17-ai-integration-analyst-says" rel="noreferrer noopener">Apple Intelligence features</a> on October 28 with the launch of iOS 18.1, offering initial AI functionalities.
The rollout will continue with iOS 18.2, including ChatGPT integration and advanced tools like Visual Intelligence and Genmoji, aiming to boost future sales.
Needham&nbsp;analyst Laura Martin expects Apple iPhone to account for up to 96% of the <a target="_blank" href="https://www.benzinga.com/news/24/09/41005053/apple-iphone-to-fuel-96-of-2025-revenue-analyst-says-a-safer-bet-than-ai-heavy-amazon-alphabet-micro" rel="noreferrer noopener">company&#8217;s 2025 revenue</a>.
International Data Corporation (IDC) had <a target="_blank" href="https://www.benzinga.com/news/24/08/40600289/apples-market-share-poised-to-gain-genai-and-iphone-16-lead-the-way-idc" rel="noreferrer noopener">reignited confidence in</a> smartphone manufacturers, including Apple, with a new market forecast projecting a 5.8% rise in global smartphone shipments to 1.23 billion units in 2024, recovering after two tough years.
The report highlighted increased demand for budget Android smartphones in China and emerging markets and strong adoption of generative AI smartphones in premium markets as key growth drivers.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42672262/hive-digital-boosts-ai-ambitions-with-30-million-nvidia-gpu-deployment" target="_blank" rel="noreferrer noopener">HIVE Digital Boosts AI Ambitions With $30 Million Nvidia GPU Deployment</a></li>
</ul>
Image via Shutterstock.

Media

GOOG

GOOGL

MSFT

NVDA

AI Smartphones To Cushion Semiconductor Industry Amid Data Center Uncertainty: Report

This appointment not only introduces strong leadership to Color Star but also strengthens the company's ties with the Middle East, particularly the UAE.

Management

Reported Earlier, Color Star Technology Says Shaikh Humaid Abdulla Rashed Ahmed Almualla, A Prominent Member Of The UAE Royal Family, Has Joined As An Independent Director

HC Wainwright &amp; Co. analyst Andrew Fein initiates coverage on Palvella Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PVLA#NASDAQ">PVLA</a>) with a Buy rating and announces Price Target of $38.

PVLA

HC Wainwright & Co. Initiates Coverage On Palvella Therapeutics with Buy Rating, Announces Price Target of $38

Raymond James analyst C. Gregory Peters downgrades Hagerty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGTY#NYSE">HGTY</a>) from Market Perform to Underperform.

Downgrades

HGTY

Raymond James Downgrades Hagerty to Underperform

Needham analyst Chris Pierce maintains ACV Auctions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACVA#NASDAQ">ACVA</a>) with a Buy and raises the price target from $26 to $28.

ACVA

Needham Maintains Buy on ACV Auctions, Raises Price Target to $28

Raymond James analyst Aaron Kessler upgrades EverQuote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVER#NASDAQ">EVER</a>) from Outperform to Strong Buy and maintains the price target from $35 to $35.

EVER

Raymond James Upgrades EverQuote to Strong Buy, Maintains Price Target to $35

Raymond James analyst C. Gregory Peters upgrades Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) from Market Perform to Outperform and announces $305 price target.

Raymond James Upgrades Progressive to Outperform, Announces $305 Price Target

Reported Earlier, Nippon Steel Extends Estimated Time To Close US Steel Merger Agreement To Q1 Of Calendar Year 2025 From Previously Expected Q3 Or Q4 Of Calendar Year 2024

Over the next three years, the GDTC plans to continue its expansion, focusing on advancing AI/ML capabilities and developing innovative digital solutions to boost operational efficiency and customer engagement.&nbsp;

Kimberly-Clark Increases Its Commitment To India Through Its Global Digital Technology Center In Bengaluru

In a recent survey conducted by&nbsp;Zoomcar Holdings, Inc. ("Zoomcar" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>), India's leading car-sharing marketplace, reported a remarkable 43% year-on-year growth in bookings for November, driven primarily by a surge in demand during the wedding season. This year's wedding season in India has been the strongest in recent years, emerging as one of the biggest contributors to this growth. With the assumption of a similar growth trend as the upcoming holiday season approaches, Zoomcar recognizes the importance of broadening and diversifying its booking channels to capture greater market potential and has revamped its website booking experience to provide a seamless and user-friendly booking experience, matching the convenience of its mobile app.
 &nbsp;

ZCAR

Zoomcar Reports 43% Booking Surge, Revamps Website Ahead of Holiday Rush

NIO Reveals Repurchase Right Notification For 0.50% Convertible Senior Notes Due 2027

BYD Co Ltd&#8216;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) contractor Jinjiang Group on Thursday said that the Brazilian authority&#8217;s portrayal of its employees working at the Chinese EV giant&#8217;s factory in Brazil as &#8220;enslaved&#8221; is &#8220;completely inconsistent with facts.&#8221;
What Happened: Jinjiang said that their workers were unjustly labeled as enslaved, making them feel insulted.
"Being unjustly labeled as ‘enslaved' has made our employees feel that their dignity has been insulted and their human rights violated, seriously hurting the dignity of the Chinese people. We have signed a joint letter to express our true feelings," Jinjiang said on Weibo, as translated by Reuters news agency.
Lin Yunfei, general manager of branding and public relations at BYD, also reposted the statement. Yunfei also alleged that the allegations are an attempt by &#8220;foreign forces&#8221; to smear Chinese brands and the country.
"In the matter of smearing Chinese brands, smearing China, and attempting to undermine the friendship between China and Brazil, we have seen how relevant foreign forces maliciously associate and deliberately smear," Yunfei said in a post on Weibo.
BYD did not immediately respond to <a href="https://pro.benzinga.com/dashboard">Benzinga&#8217;s</a> request for comment.
Why It Matters: Brazilian authorities said on Monday that they have <a href="https://www.benzinga.com/government/regulations/24/12/42667814/brazil-authorities-halt-work-at-byd-factory-site-after-workers-found-in-slavery-like-conditions">halted the construction of the plant that BYD&nbsp;is building in Salvador</a>, Bahia after finding workers living and working in conditions analogous to "slavery."
Authorities ordered that the construction of the factory in Bahia be stopped after rescuing 163 people working at the site, according to a statement by the Labor Prosecutor's Office (MPT).
The authorities shut down the workers' lodgings and communicated the same to both BYD and construction firm Jinjiang Construction Brazil Ltd, one of the contractors hired by the company to carry out the construction, it added.
The MPT also noted that the conditions constituted "forced labor." If a worker were to terminate their employment contract after six months, they would leave the country without any pay for their work since the company deducted their airfare to and from Brazil, in addition to other costs, the statement said.
BYD was planning to start production at the factory in Brazil in 2025. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/12/42668333/tesla-model-x-lucid-gravity-or-rivian-r1s-which-three-row-electric-suv-is-a-better-buy" target="_blank" rel="noreferrer noopener">Tesla Model X, Lucid Gravity Or Rivian R1S: Which Three-Row Electric SUV Is A Better Buy?</a></li>
</ul>
Photo courtesy: Shutterstock

Regulations

BYDDY

BYD Contractor Denies Allegations Of 'Slavery-Like' Working Conditions At Factory Site In Brazil

The CNN Money Fear and Greed index showed a further easing in the fear level, while the index remained in the &#8220;Fear&#8221; zone on Tuesday.
U.S. stocks settled higher on Tuesday, with the S&amp;P 500 jumping over 1% on Christmas Eve. Shares of Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained more than 7%, while Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) edged higher by 0.4% during the session.
The New York Stock Exchange closed early Tuesday for Christmas Eve and was also shut on Wednesday for Christmas Day.
On the economic data front, the U.S. Redbook index increased 5.9% year-over-year in the latest week, following a prior reading of a 4.8% gain. The composite manufacturing index in the U.S. Fifth District increased to -10 in December compared to a reading of -14 in the previous month.
All sectors on the S&amp;P 500 closed on a positive note, with consumer discretionary, financial, and information technology stocks recording the biggest gains on Tuesday.
The Dow Jones closed higher by around 390 points to 43,297.03 on Tuesday. The S&amp;P 500 rose 1.10% to 6,040.04, while the Nasdaq Composite surged 1.35% at 20,031.13 during Tuesday's session.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 34, the index remained in the &#8220;Fear&#8221; zone on Tuesday, versus a prior reading of 29.6.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42669200/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Stocks With Over 4% Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

Long Ideas

TSLA

S&P 500 Surges Over 1% As Santa Rally Kicks Off, Tesla, Nvidia Gain: Greed Index Remains In 'Fear' Zone

FibroBiologics reports 9M results

FibroBiologics, Inc. ( ($FBLG) ) has released its Q3 earnings. Here is a breakdown of the information FibroBiologics, Inc. presented to its investo...

FibroBiologics Reports Q3 2024 Financial Results

FibroBiologics (FBLG) announced the filing of a patent application with the United States Patent and Trademark Office covering methods employing fi...

FibroBiologics files patent application on reduction of clots related to IBMIR

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on FibroBiologics, Inc. (FBLG – Research Report). The associated price t...

Promising Developments and Financial Stability Highlight FibroBiologics' Near-Term Opportunities

FibroBiologics (FBLG) announced the filing of a patent application covering methods for treatment of splenomegaly using a cell-based therapeutic ap...

FibroBiologics files patent application for cell-based therapeutic

Rodman & Renshaw initiated coverage of FibroBiologics (FBLG) with a Buy rating and $12 price target Published first on TheFly – the ultimate source...

FibroBiologics initiated with a Buy at Rodman & Renshaw

FibroBiologics, Inc. ( ($FBLG) ) has issued an announcement. FibroBiologics, Inc. has entered into a Side Letter Agreement with GEM Global Yield LL...

FibroBiologics Resolves Commitments Through Share Issuance Agreement

FibroBiologics (FBLG) has entered into a Standby Equity Purchase Agreement with YA II PN, an investment fund managed by Yorkville Advisors Global. ...

FibroBiologics announces $25M financing

The latest update is out from FibroBiologics, Inc. ( ($FBLG) ). FibroBiologics, Inc. announced a $25 million Standby Equity Purchase Agreement with...

FibroBiologics Secures $25M Equity Agreement for Trials

FibroBiologics announces $25 million financing

Press Releases

FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa

FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit

Health Care

Legal

FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office

FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases

FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024

FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology

FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics

FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly

Financing

FibroBiologics Announces $25 Million Financing

Aadi Bioscience

Adicet Bio

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Anixa Biosciences

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

Avalo Therapeutics

bluebird bio

Coya Therapeutics

CytomX Therapeutics

Genelux

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

I-MAB

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Nuvectis Pharma

OS Therapies

PMV Pharma

Quince Therapeutics

Skye Bioscience

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Exagen

Rodman & Renshaw

D. Boral Capital

HC Wainwright & Co.

EF Hutton

Comments

FibroBiologics

FibroBiologics (FBLG) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga